Insmed Q3 2023 Earnings Report

Insmed EPS Results

• Actual EPS: -$1.10
• Consensus EPS: -$1.06
• Beat/Miss: Missed by -$0.04
• One Year Ago EPS: N/A

Insmed Revenue Results

• Actual Revenue: $79.07 million
• Expected Revenue: $78.86 million
• Beat/Miss: Beat by +$210.00 thousand
• YoY Revenue Growth: N/A

Insmed Announcement Details

• Quarter: Q3 2023
• Date: 10/26/2023
• Time: N/A

Insmed (NASDAQ:INSM) is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.